Navigation Links
Multiple Sclerosis: Treatment and Global Market 2014-2019
Date:7/8/2015

DUBLIN, July 01, 2015 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/3d9g5t/multiple) has announced the addition of the "Multiple Sclerosis: Treatment and Global Market" report to their offering.

This report cover's the latest pharmaceutical global market insights for Multiple Sclerosis (MS) disease treatments and provides market forecasts, trends, pipelines, patent analysis and profiles of major players within the markets.

Report Highlights:

- The report provides the forecast of global market for Multiple Sclerosis (MS) disease treatments and projections of compound annual growth rates (CAGRs) over the next five years from 2014 to 2019.
- This report make available an invaluable tool for business planners, acquisitions specialists, licensing strategists, product managers, market research analysts, investors, consultant, members of the pharmaceutical, healthcare and biotechnology industries and anyone interested in the MS disease and its future.
- The importance of identifying overall market trends production opportunities, emerging geographic merger and acquisition opportunities, and insights that provides guidance for the sales growth.
- Discussion on market drivers and inhibitors, and the area of unmet clinical need.
- Information on the regulatory environment and impacts of appovals. agencies.
- Determines the current status of the market for disease-modifying multiple sclerosis (MS) drugs, biologics and vaccines, and to assess their growth potential over a five-year period from 2014 through 2019.
- Special focus is placed on how new products and technologies will affect current market leaders in the MS treatment sector.
- Report presents detailed profiles of the MS disease-modifying products on the market around the world and in the U.S.
- Report covers about all products in the Phase I, II and III stages of clinical development of disease-modifying products and some unique treatments for preclinical stage of development of the disease.
- Report presents detailed profiles of major companies focusing on their development, and international aspects affecting these products.
- Company profiles of all major companies in this segment.

Key Topics Covered:

1 Executive Summary

2 Disease: Introduction
2.1 Disease Overview
2.2 Disease Classification & Types
2.3 Etiology
2.4 Pathophysiology
2.5 Prognosis
2.6 Pharmacoeconomic Burden
2.7 Epidemiology (by geography wherever possible)
2.8 Diagnosis
2.9 Treatment and Management (by geography wherever possible)
2.10 Referral Pathway

3 Market Size: Historical and Forecast
3.1 Global Market - Forecast

4 Drivers and Barriers for the Market

5 Unmet Need Analysis
5.1 Product Profiles for the Major Marketed Products
5.1.1 Product Overview
5.1.2 Efficacy
5.1.3 Safety
5.1.4 Clinical Studies
5.1.5 Current Market Size and Future Assessment
5.1.6 SWOT

6 Pipeline Analysis
6.1 Overview
6.2 Overall Pipeline by Phases of Development
6.3 Registration Phase
6.4 Phase III Pipeline
6.5 Phase II/III Pipeline
6.6 Phase II Pipeline
6.7 Phase I/II Pipeline
6.8 Phase I Pipeline
6.9 IND Filed
6.10 Preclinical Phase
6.11 Discovery Pipeline

7 Key Events and Likely Impact on the Future Market

8 Future Competitive Scenario
8.1 Future Players
8.2 Profiles of Future Players

9 Regulatory aspects

10 Patent Evaluation
10.1 Patent length and market exclusivity

11 Major companies and market share

12 Appendix
12.1 Abbreviations
12.2 Research Methodology
12.3 Disclaimer

13 List of Tables

14 List of Figures

For more information visit http://www.researchandmarkets.com/research/3d9g5t/multiple

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Non-Insured Health Benefits Program Approves AUBAGIO(TM) for Relapsing Remitting Multiple Sclerosis
2. Clinical Experts Report on How Varian Technology Can Be Used for the Precise, Noninvasive, Simultaneous Treatment of Multiple Metastases in the Brain, Spine, Head & Neck, and Lung
3. Janssen Initiates Rolling Submission of Biologic License Application (BLA) for daratumumab with U.S. FDA for the Treatment of Multiple Myeloma
4. Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types
5. AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting
6. People Around The World Are Sharing What Makes Them Stronger Than Multiple Sclerosis
7. DDW-Präsentation untersucht die vielseitige und wirkungsvolle Behandlung von GERD durch Stretta in multiplen Patientengruppen
8. DDW Presentation Examines Stretta As A Versatile And Effective GERD Treatment For Multiple Patient Populations
9. Multiple Studies at American Urological Association Annual Meeting Highlight Accuracy, Broad Applicability of GenomeDxs Decipher Test for Prostate Cancer
10. Boston Biomedical to Highlight Data Examining Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types at ASCO 2015
11. CorTechs Labs kündigt Partnerschaft für die Bereitstellung umfassender Lösungen zur Quantifizierung des Verlustes von Hirnvolumen bei multipler Sklerose an
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/12/2017)... 12, 2017   EcoVadis , the leading platform for environmental, social ... annual edition of its Global CSR Risk and Performance Index. The report ... based on Scorecard Ratings that analyzed nearly 800,000 data points across the ... ... ...
Breaking Medicine Technology:
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
(Date:10/12/2017)... BALTIMORE (PRWEB) , ... October 12, 2017 , ... ... average of $3,296 in property taxes a year. In some states—like New York, ... higher. , By contrast, many overseas retirement havens have extremely low property-tax rates, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... University of California Berkeley, and other leading institutions in announcing the launch of ... institutions to change the way animals are raised for food. , Founding members ...
(Date:10/12/2017)... ... October 12, 2017 , ... Nvision Biomedical Technologies ... with the addition of industry sales leader, Thomas (Tom) Slott, as Senior Vice ... distribution and sales network, direct the efforts of the surgical sales teams, manage ...
Breaking Medicine News(10 mins):